NCT05483933 2025-12-23Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian CancersShattuck Labs, Inc.Phase 1 Completed86 enrolled 17 charts
NCT03552471 2025-02-13Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerOhio State University Comprehensive Cancer CenterPhase 1 Completed25 enrolled
NCT02996825 2024-04-02Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast CancerCity of Hope Medical CenterPhase 1 Completed44 enrolled